Bacterial-engineered self-stabilizing ultra-small AgCu nanoparticles for dual antimicrobial-anticancer therapy.

Area of Science:

• Nanotechnology
• Materials Science
• Biomedical Engineering

Background:

• Bimetallic silver-copper nanoparticles (AgCu NPs) show promise but face challenges in stability and biocompatibility for clinical applications.
• Existing AgCu NPs often lack the necessary characteristics for effective therapeutic use.
• Developing stable and effective nanomaterials is crucial for combating drug-resistant bacteria and cancer.

Purpose of the Study:

• To develop ultra-small AgCu NPs (US-AgCu NPs) with enhanced dual antimicrobial and antitumor functionalities.
• To investigate a novel bacterial incubation-driven synthesis method for producing stable AgCu NPs.
• To address the limitations of conventional AgCu NPs, including poor stability and biocompatibility.

Main Methods:

• Synthesis of AgCu NPs using a bacterial incubation-driven dynamic nanoreactor approach.
• Characterization of nanoparticle size reduction from 15 nm to 2 nm upon interaction with bacteria (E. coli, S. aureus).
• Mechanistic studies involving Ag+ release, oxidative dissolution, and biomolecule-mediated re-nucleation.

Main Results:

• Spontaneous size reduction of AgCu NPs to 2 nm via bacterial interaction, forming stable, protein-capped dispersions.
• Demonstrated synergistic therapeutic advantages including enhanced antibacterial potency and pH-selective cytotoxicity.
• Achieved reusable antimicrobial performance with minimal resistance development and long-term stability.

Conclusions:

• Bacterial-enabled dynamic nanoreactor synthesis offers a scalable, kilogram-level production method for therapeutic NPs via continuous fermentation.
• US-AgCu NPs present a promising bio-derived strategy for combating antimicrobial resistance and malignancies.
• This approach overcomes critical manufacturing challenges for nanomaterials in therapeutic applications.